Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Camrelizumab (SHR-1210) in Healthy Subjects
NCT05799183Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of camrelizumab in advanced cancer (4 arms), sponsored by Hengrui. Primary endpoints: Incidence and severity of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest, Area Under the Concentration-Time Curve from time zero to infinity and 2 more. Started Jul 2023; status: terminated.
02
Drugs
camrelizumab
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT05799183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799183.